

NZX and Media Release

4 October 2018

NZX Limited

WELLINGTON

TruScreen Announces New Chairman

TruScreen Limited (NZAX: TRU)

Cervical cancer technology company, TruScreen Limited (NZAX:TRU, or "the Company") announces that Mr Robert Hunter has been replaced by Mr Anthony (Tony) Ho as Chairman of the company.

Mr Hunter who was the founder and initial Chairman of TruScreen, recently announced his decision to step down from the chairmanship at the 2018 AGM.

The board is pleased to advise that Mr Tony Ho has been appointed as the replacement Chairman. Tony is an experienced company director with over 25 years' experience in diverse industries, including resources, services, biotech, consumer goods wholesale and retail. He holds a Commerce degree from the University of New South Wales, Sydney. He is a Chartered Accountant and a fellow of the Australian Institute of Company Directors, Chartered Institute of Secretaries and Administrators and the Governance Institute of Australia.

Mr Hunter who remains a significant shareholder was re-elected to the board at the recent AGM and will continue to serve as a non-executive director.

Martin Dillon CEO

-ENDS-

For more information visit www.truscreen.com

Contact Martin Dillon

TruScreen Chief Executive Officer

Email: martindillon@truscreen.com



About TruScreen:

TruScreen's real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.

